Pharma earnings season starts with corporate profits, new CEOs taking center stage
Quarterly earnings kick off in earnest this week, with a handful of the largest biopharma companies set to report how they’re doing midway through 2023.
While investors and analysts will be closely watching some CEOs settle into new roles with new strategies, last week’s earnings from Johnson & Johnson and Novartis also serve as a reminder of a simple lesson: Investors want beat-and-raise quarters with no surprises.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.